drugset / Trial / NCT05444530
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).
Timeline
- Start
- 2022-07-21
- Primary completion
- 2025-06-24
- Completion
- 2025-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | VAC85135 | Vaccine | — | Intramuscular |